Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary
14/04/2025 22:01
Lexaria Bioscience Corp LEXX.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ended February 28, lower than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of two analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -17 cents to -14 cents per share. Revenue was $174.00 thousand; analysts expected $137.00 thousand. Lexaria Bioscience Corp's reported EPS for the quarter was a loss of 15 cents. The company reported a quarterly loss of $2.71 million. Lexaria Bioscience Corp shares had fallen by 21.1% this quarter and lost 35.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 40.9% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Lexaria Bioscience Corp is $7.50 This summary was machine generated from LSEG data April 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Feb. 28 2025 | -0.15 | -0.15 | Met |
| Nov. 30 2024 | -0.12 | -0.16 | Missed |
| Aug. 31 2024 | -0.11 | -0.14 | Missed |
| May. 31 2024 | -0.10 | -0.13 | Missed |